Intellectual property

Intellectual property and technology collaboration

Partners need to know what OncoFirm has filed, what happens to their own IP and who owns what a joint project produces. This page answers those questions.

Discuss licensing or joint development
See partner agreements

What OncoFirm has filed

OncoFirm has filed six patent applications and three trademark applications relating to its platform, as announced on 3 August 2026. The filings relate to:

  • Fluorescence-enhanced lateral flow diagnostic technologies
  • Multi-biomarker detection platforms
  • AI-assisted diagnostic interpretation
  • Digital handheld reader systems
  • Oncology software platforms
  • Assay design and biomarker detection methods

These are applications. They are subject to examination by the relevant patent and trademark offices, and no assurance can be given that any will be granted or registered.

How IP works in a collaboration

Background IP stays put

What each party owned before the project remains its own. Access is granted only as needed for the project.

Project IP is agreed up front

Ownership of inventions made during the work, and each party’s rights to use them, are written into the agreement before work starts.

Funder rules apply

For federally funded work, U.S. law generally lets the recipient elect title to inventions made under the award, with a license and certain other rights reserved to the government. That can include inventions first reduced to practice under the award.

Publication is protected

Academic partners keep the right to publish, with a short, defined review period to allow patent filing.

Materials and data are documented

Transfers of specimens, reagents and data happen under material transfer or data use agreements.

Confidentiality comes first

Technical detail is exchanged only after a confidentiality agreement is signed.

Technology we would like to hear about

We are interested in licensing, co-development and joint research involving:

  • Patented or patent-pending cancer biomarkers
  • Antibodies and antibody pairs for protein biomarkers
  • Assay chemistries and fluorescent labels
  • Optical detection and reader technology
  • Software and algorithms for assay signal interpretation
  • Complementary point-of-care technologies

Technology-transfer offices can send a non-confidential summary through the collaboration inquiry form. Where a technology fits one of our research priorities, we can build a joint proposal around it under one of the grant programs we are pursuing.

Frequently asked questions

No. The applications are pending and none has been granted.

Evaluation under a material transfer or evaluation agreement can be arranged as prototypes mature.

Notice

This page is general information, not legal advice. Terms for any collaboration are set out in the signed agreement between the parties.

OncoFirm™ technologies described on this site are in research and development. Their performance characteristics have not been established, and no OncoFirm product has been cleared, approved or authorized by the U.S. Food and Drug Administration. Nothing here is medical advice. Reference to a federal agency or funding program does not imply endorsement, funding, sponsorship or affiliation.